跳到正文
Brand AI

莫德纳

争议事件

以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。

返回词条共 3 条

  1. 2022

    Alnylam 就脂质专利起诉 Moderna 和 Pfizer

    提起诉讼

    Alnylam 在特拉华州联邦法院起诉 Moderna 和 Pfizer，指控两家公司的新冠疫苗侵犯其可生物降解脂质专利。Alnylam 称其寻求金钱赔偿，并表示无意阻碍疫苗销售、生产或分销。Moderna 否认相关指控；报道刊出时 Pfizer 尚未回应媒体。

    品牌回应

    • 否认 — Moderna

      “Moderna’s LNPs do not resemble Alnylam’s work, and any assertion that the Alnylam patent covers Moderna’s Covid-19 vaccine is specious,” the company said.

    来源摘录

    • Alnylam alleges that the company’s FDA-approved Covid vaccine, Spikevax, uses biodegradable LNP technology that infringes on the biodegradable lipids patent.
    • The two lawsuits were filed Thursday in federal court in Delaware.
    • Alnylam did not have similar meetings with Pfizer or BioNTech, but the company claims that their FDA-approved Covid vaccine, Comirnaty, uses LNPs that infringe the same patent.
    来源

  2. 2022

    Genevant就疫苗相关专利起诉Moderna

    提起诉讼

    Moderna在美国面临一宗涉及其新冠疫苗所用脂质纳米颗粒技术的专利侵权诉讼。Genevant称Moderna侵犯了由Arbutus Biopharma开发并授权给Genevant的六项美国专利所涵盖的技术，并寻求收取专利使用费。Moderna否认相关指控，并表示将通过法院抗辩。

    品牌回应

    • 否认 — Moderna

      Moderna denies these allegations, and will vigorously defend itself against Genevant’s claims in Court.

    来源摘录

    • Covid-19 vaccine producer Moderna faces a patent infringement lawsuit in the US, relating to the lipid nanoparticles (LNPs) that protect the mRNA in its vaccine.
    • In a statement, Moderna said it was aware of the alleged patent infringements. ‘Moderna denies these allegations, and will vigorously defend itself against Genevant’s claims in Court.
    • The suit claims Moderna is infringing technology from six US patents, developed by Arbutus Biopharma and licensed to Genevant – a joint venture between Arbutus and Roivant Sciences.
    来源

  3. 2020

    Moderna披露疫苗文件在网络攻击中遭访问

    问题披露

    Moderna表示，欧洲药品管理局告知其，与该公司新冠候选疫苗提交前讨论有关的部分文件在针对该监管机构的网络攻击中遭到非法访问。据Moderna称，其提交材料不包含可识别个别研究参与者的信息。该公司披露了这一通知，但未就遭访问的文件或攻击本身提供更多细节。

    来源摘录

    • Moderna Inc has recently stated that it was informed by the official European Medicine Agency or EMA that certain documents that were related to the pre-submission talks of its own COVID-19 vaccine candidate were said to be unlawfully accessed in a cyberattack on the known medicines regulator.
    • Moderna has stated that its submission to the EMA actually did not include any information that identified certain individual study participants.
    来源